Peter Heerma

CIK: 0001789617

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)19 (52.8%)

Position reduction

Option Exercises (M)10 (27.8%)

Derivative conversions

Awards (A)5 (13.9%)

Compensation grants

Other (G, F, J, C, D, …)2 (5.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TVTX

Travere Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (36 total)

TVTX
Travere Therapeutics, Inc.
Sep 17, 2026
Exercise(M)
Direct
8.3K shares at avg. $22.40$186K
TVTX
Travere Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
8.3K shares at avg. $65.07$539K
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Exercise(M)
Direct
100K shares at avg. $11.25$1.1M
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Exercise(M)
Direct
17.7K shares at avg. $26.88$476K
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Exercise(M)
Direct
55K shares at avg. $15.46$850K
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Sale(S)
Direct
93.6K shares at avg. $63.25$5.9M
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Sale(S)
Direct
79.1K shares at avg. $63.65$5.0M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
1.4K shares at avg. $22.40$31K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
39.3K shares at avg. $26.88$1.1M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
1.4K shares at avg. $65.31$93K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
1.4K shares at avg. $63.65$89K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
27.4K shares at avg. $62.59$1.7M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
71.9K shares at avg. $62.05$4.5M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
36.5K shares at avg. $8.93$326K
TVTX
Travere Therapeutics, Inc.
May 5, 2026
Sale(S)
Direct
2.2K shares at avg. $46.65$101K
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Award(A)
Performance-based restricted stock units
Direct
8.5K shares-
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Exercise(M)
Direct
4.3K shares-
TVTX
Travere Therapeutics, Inc.
Apr 14, 2026
Sale(S)
Direct
7.2K shares at avg. $41.93$303K
TVTX
Travere Therapeutics, Inc.
Apr 13, 2026
Award(A)
Direct
14K shares-
TVTX
Travere Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
7.3K shares at avg. $32.12$235K
TVTX
Travere Therapeutics, Inc.
Jan 31, 2026
Award(A)
Direct
26.1K shares-
TVTX
Travere Therapeutics, Inc.
Dec 24, 2025
Sale(S)
Direct
5K shares at avg. $40.00$199K
TVTX
Travere Therapeutics, Inc.
Nov 3, 2025
Gift(G)
Direct
1.1K shares-
TVTX
Travere Therapeutics, Inc.
Oct 31, 2025
Sale(S)
Direct
5.6K shares at avg. $35.00$196K
TVTX
Travere Therapeutics, Inc.
Oct 28, 2025
Sale(S)
Direct
2.7K shares at avg. $30.00$80K

		Type	Shares	Price		Ownership
Sep 17, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	8,282	$22.40	$185,517	Direct
Sep 17, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	8,282	$65.07	$538,917	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	100,000	$11.25	$1,125,000	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	17,717	$26.88	$476,233	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	55,000	$15.46	$850,300	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	93,604	$63.25	$5,920,182	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	79,113	$63.65	$5,035,906	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	1,381	$22.40	$30,934	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	39,283	$26.88	$1,055,927	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,431	$65.31	$93,458	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,400	$63.65	$89,113	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	27,421	$62.59	$1,716,379	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	71,938	$62.05	$4,463,875	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	36,526	$8.93	$326,177	Direct
May 5, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	2,174	$46.65	$101,417	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Award(A) Performance-based restricted stock units	8,500	-	-	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	4,250	-	$0	Direct
Apr 14, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	7,215	$41.93	$302,516	Direct
Apr 13, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	14,000	-	$0	Direct
Feb 3, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	7,310	$32.12	$234,797	Direct
Jan 31, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	26,120	-	$0	Direct
Dec 24, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	4,980	$40.00	$199,200	Direct
Nov 3, 2025	TVTX Travere Therapeutics, Inc.	Gift(G)	1,078	-	-	Direct
Oct 31, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	5,591	$35.00	$195,685	Direct
Oct 28, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	2,662	$30.00	$79,860	Direct

1-25 of 36 transactions

About Heerma Peter

Heerma Peter (SEC CIK 0001789617) files insider reports with the SEC as EVP, CHIEF COMMERCIAL OFFICER of Travere Therapeutics, Inc. (TVTX).

Signal8 holds 13 ownership filings by Heerma Peter, all Form 4s, filed between Sep 9, 2024 and Sep 17, 2026. Those filings report 36 transactions, from Sep 5, 2024 to Sep 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Heerma Peter's filings is in SAN DIEGO, CA.

Recent filings by Heerma Peter

Sep 17, 2026: Option exercise of TVTX shares (Form 4, code M).
Sep 17, 2026: Open-market sale of TVTX shares (Form 4, code S).
Sep 16, 2026: Option exercises of TVTX shares (3 lines, Form 4, code M).
Sep 16, 2026: Open-market sales of TVTX shares (2 lines, Form 4, code S).
Sep 15, 2026: Option exercises of TVTX shares (2 lines, Form 4, code M).

Other insiders filing for Travere Therapeutics, Inc. (TVTX)

Dube Eric M, CHIEF EXECUTIVE OFFICER
ROTE WILLIAM E., Chief Research Officer
Inrig Jula, EVP, Head of R&D & CMO
REED ELIZABETH E, Chief Legal Officer and GC
Cline Christopher R., CHIEF FINANCIAL OFFICER
Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER

How to read Form 4 transaction codes